• Mashup Score: 0

    Outcomes once deemed “almost too good to be true” disappeared with longer follow-up in an all-comer population of patients with diabetes undergoing revascularization.

    Tweet Tweets with this article
    • Despite a promising start, extended follow-up from the SUGAR trial found that the Cre8 EVO DES could not maintain superiority over the Resolute Onyx DES at 2 years in patients with diabetes undergoing revascularization for CAD. #TCT2022 #CardioTwitter https://t.co/dOeEinFBaa https://t.co/PBmmQuSiyJ

  • Mashup Score: 0

    At TCT 2022, Dr. Akl Fahed, Physician-scientist and Interventional Cardiologist, Massachusetts General Hospital and Harvard Medical School, and Dr. Ozan Unlu, fellow in cardiovascular medicine and Brigham and Women’s Hospital and Harvard Medical School, co-presented on Unique Features of Coronary Artery Disease in Women. Here is a summary of their findings.   Related TCT 2022 Coverage:…

    Tweet Tweets with this article
    • @DAICeditor @TCTConference @BWHCVImaging @harvardmed At #TCT2022, Dr. #Akl_Fahed and Dr. #Ozan_Unlu co-presented on Unique Features of #CoronaryArteryDisease in #Women. Watch the video to learn more about their findings: https://t.co/sCTYr0MOrD

  • Mashup Score: 0

    The 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation (CRF), was held Sept. 16-20 in Boston, MA. For those of us on hand for the event, and others who participated virtually, it was clear how TCT has become the premier educational meeting specializing in interventional cardiovascular medicine. This year’s blockbuster…

    Tweet Tweets with this article
    • @DAICeditor @TCTConference @crfheart As recounted by #CRF #leadership, #TCT2022 gathered leading #researchers and #clinicians from around the world who presented and discussed the latest evidence-based research in the field: https://t.co/aatsBlEclH

  • Mashup Score: 0

    The Photo Gallery includes images taken by DAIC’s editorial team at the 34th Transcatheter Cardiovascular Therapeutics (TCT) annual scientific symposium of the Cardiovascular Research Foundation (CRF), held in Boston in September. This gallery includes images of the education, trends and technology found throughout the conference. You can find more TCT22 coverage here.

    Tweet Tweets with this article
    • @DAICeditor @TCTConference @crfheart Be sure to check out the #PhotoGallery that includes images from the #Transcatheter #Cardiovascular #Therapeutics (#TCT) annual #scientific #symposium of the Cardiovascular Research Foundation (#CRF):https://t.co/kwEJ4mcWD4 #tct2022

  • Mashup Score: 0

    Survival was better with CABG, though not in one subgroup. Still, the goal of PCI in the real world, one observer says, may not be to extend life, but ‘to get short-term symptom relief.’

    Tweet Tweets with this article
    • Randomized comparisons of PCI and CABG for left-main coronary disease, naturally enrolled patients suitable for either procedure. But that takes a toll on their relevance to clinical practice, where patients are not so narrowly defined. #TCT2022 https://t.co/i5RvyF6w4f